PPP6R2

Across TCGA pan-cancer cohorts, PPP6R2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PPP6R2 data layer compared with 24 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher PPP6R2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPP6R2 expression acts as an unfavorable survival marker.

KICH, OV, and HNSC are the cancer types where PPP6R2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
OV	DFS	Median	All	0.104	0.541	<.001	18	view →
HNSC	DFS	Median	All	0.132	0.712	<.001	18	view →
BLCA	DFS	Median	All	0.179	0.625	.029	12	view →
COAD	OS	Median	All	0.242	0.687	.027	8	view →
ESCA	DFS	Median	II,III,IV	0.275	0.529	.042	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
LGG	DFS	Median	All	0.110	0.826	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PPP6R2–KICH (DFS)

Open the KICH breakdown →